We focus on assisting our customers in biotechnology research and advancing the process of new drug development.
Medicilon Overview
Since the founding of our company in 2004, Medicilon (stock code : 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, we keep improving our service system in biotechnology and pharmaceutical research. Our service now spans cross medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.
In the past 17 years, we have worked with more than 940 clients worldwide on their scientific research, among which more than 100 cases successfully gained certifications for Phase I clinical trials. Our research team is capable of, but not limited to the medicinal research of small molecule chemicals, antibody, PROTAC, ADC, CAR-T, etc.
Medicilon is fully accredited by the International Laboratory Animal Assessment and Accreditation (AAALAC) and in compliance with the US Food and Drug Administration(US FDA)’s Good Laboratory Practice(GLP). The standard of laboratories is certified by the National Medical Products Administration (NMPA) for GLP compliance.
Our headquarters is located in Zhangjiang High-Tech Park, with two branches in Chuansha Economic Park and Nanhui high-tech Park, covering a total area of over 738,000 sq. ft. We have a strong technical team of over 1,642 employees, among which more than 50% have advanced degrees and more than 10% have foreign education and/or work experience.
